AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / MEDICINAL CHEMICALS & BOTANICAL PRODUCTS
Regencell Bioscience Holdings Limited Ordinary Shares
XNAS · usd
SIC 7832 · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS
FIGI BBG001S97125
7.67▼ 2.14 (-21.81%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
9.81
Day's Range
7.55 – 9.82
52-Week Range
4.51 – 69.00
Volume
473.6K
Avg Volume
293.4K
Share Statistics
Shares Outstanding
Employees
10
Exchange
XNAS
Listed
2021-07-16
Share count as of June 30, 2026

Regencell Bioscience Holdings Limited Ordinary Shares (RGC) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Regencell Bioscience Holdings Limited Ordinary Shares (RGC)
What is Regencell Bioscience Holdings Limited Ordinary Shares's Market Cap?
Regencell Bioscience Holdings Limited Ordinary Shares's Market Cap is $3.8B, based on as-reported figures from SEC (XBRL) filings.
What is Regencell Bioscience Holdings Limited Ordinary Shares's Enterprise Value?
Regencell Bioscience Holdings Limited Ordinary Shares's Enterprise Value is $3.8B, based on as-reported figures from SEC (XBRL) filings.
What is Regencell Bioscience Holdings Limited Ordinary Shares's EV / EBITDA?
Regencell Bioscience Holdings Limited Ordinary Shares's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Regencell Bioscience Holdings Limited Ordinary Shares's Net Income (TTM)?
Regencell Bioscience Holdings Limited Ordinary Shares's Net Income (TTM) is -$3.6M, based on as-reported figures from SEC (XBRL) filings.
What is Regencell Bioscience Holdings Limited Ordinary Shares's EBITDA?
Regencell Bioscience Holdings Limited Ordinary Shares's EBITDA is -$3.7M, based on as-reported figures from SEC (XBRL) filings.
What is Regencell Bioscience Holdings Limited Ordinary Shares's Diluted EPS (TTM)?
Regencell Bioscience Holdings Limited Ordinary Shares's Diluted EPS (TTM) is -0.01, based on as-reported figures from SEC (XBRL) filings.
What is Regencell Bioscience Holdings Limited Ordinary Shares's Net Debt?
Regencell Bioscience Holdings Limited Ordinary Shares's Net Debt is -$4.9M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · RGCAs-filed SEC (XBRL) data
No Quarterly data available for this company — showing Annual instead. This company files annual reports only — foreign private issuers (Form 20-F / 40-F) are not required to file quarterly reports, so no quarterly figures exist to show.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Jun 30, 2025Jun 30, 2024Jun 30, 2023Jun 30, 2022Jun 30, 2021Jun 30, 2020Jun 30, 2019
OPERATING EXPENSES:
Selling and marketing
General and administrative (including share-based compensation of $3.22 million, $0.20 million and $0.48 million for the years ended June 30, 2026, 2025 and 2024 respectively)
Research and development (including share-based compensation of $2.42 thousand and $0.04 million, reversal of share-based compensation of $0.03 million for the years ended June 30, 2026, 2025 and 2024 respectively)
Total operating expenses
LOSS FROM OPERATIONS
OTHER INCOME, NET
LOSS BEFORE INCOME TAXES
NET LOSS
NET LOSS ATTRIBUTABLE TO:
Shareholders of the Company
Non-controlling interest—
Net loss
NET COMPREHENSIVE LOSS ATTRIBUTABLE TO:
Basic (in Dollars per share)
Diluted (in Dollars per share)